These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26817640)

  • 1. Assessing herd immunity against rubella in Japan: a retrospective seroepidemiological analysis of age-dependent transmission dynamics.
    Kinoshita R; Nishiura H
    BMJ Open; 2016 Jan; 6(1):e009928. PubMed ID: 26817640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the population susceptible to rubella in Japan, 2020: Fine-scale risk mapping.
    Kinoshita R; Arai S; Suzuki M; Nishiura H
    J Infect Public Health; 2024 Jun; 17(6):947-955. PubMed ID: 38608455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling a Supplementary Vaccination Program of Rubella Using the 2012⁻2013 Epidemic Data in Japan.
    Kayano T; Lee H; Nishiura H
    Int J Environ Res Public Health; 2019 Apr; 16(8):. PubMed ID: 31027277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the immunizing effect of the rubella epidemic in Japan, 2012-14.
    Nishiura H; Kinoshita R; Miyamatsu Y; Mizumoto K
    Int J Infect Dis; 2015 Sep; 38():16-8. PubMed ID: 26183414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy.
    Alleman MM; Wannemuehler KA; Hao L; Perelygina L; Icenogle JP; Vynnycky E; Fwamba F; Edidi S; Mulumba A; Sidibe K; Reef SE
    Vaccine; 2016 Dec; 34(51):6502-6511. PubMed ID: 27866768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Effectiveness and Cost-Benefit of Test-and-Vaccinate Policy for Supplementary Vaccination against Rubella with Limited Doses.
    Saito MM; Ejima K; Kinoshita R; Nishiura H
    Int J Environ Res Public Health; 2018 Mar; 15(4):. PubMed ID: 29565821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying geographic areas at risk of rubella epidemics in Japan using seroepidemiological data.
    Kayano T; Lee H; Kinoshita R; Nishiura H
    Int J Infect Dis; 2021 Jan; 102():203-211. PubMed ID: 33010463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of rubella and congenital rubella syndrome in Japan before 1989.
    Ueda K
    Vaccine; 2016 Apr; 34(16):1971-4. PubMed ID: 26469722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroepidemiologic studies on rubella in Fukuoka in southern Japan during 1965-1981: rubella epidemic pattern, endemicity and immunity gap.
    Ueda K; Nonaka S; Yoshikawa H; Sasaki F; Segawa K; Fujii H; Tasaki H; Shin H; Tokugawa K; Sato T
    Int J Epidemiol; 1983 Dec; 12(4):450-4. PubMed ID: 6654567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declining seroprevalence of rubella antibodies among young Israeli adults: a 12-year comparison.
    Huerta M; Davidovitch N; Ankol OE; Zaaide Y; Grotto I; Balicer RD; Zangvil E
    Prev Med; 2004 Dec; 39(6):1223-6. PubMed ID: 15539059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of rubella among Jordanian women of childbearing age.
    Jarour N; Hayajneh WA; Balbeesi A; Otoom H; Al-Shurman A; Kharabsheh S
    Vaccine; 2007 May; 25(18):3615-8. PubMed ID: 17280747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rubella Resurgence in Japan 2018-2019.
    Ujiie M
    J Travel Med; 2019 Sep; 26(6):. PubMed ID: 31259366
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of rubella seroepidemiological data for assessment of previous vaccination policy and for decision making in response to epidemics in Israel.
    Cohen D; Muhsen Kh; Aboudy Y; Harari H; Mendelson E; Green MS
    Vaccine; 2006 Jul; 24(27-28):5604-8. PubMed ID: 16716460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroepidemiological survey of rubella immunity among three populations in Shiraz, Islamic Republic of Iran.
    Doroudchi M; Dehaghani AS; Emad K; Ghaderi AA
    East Mediterr Health J; 2001; 7(1-2):128-38. PubMed ID: 12596962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of Immunity Acquired after a Single Dose of Rubella Vaccine in Japan.
    Okafuji T; Okafuji T; Nakayama T
    Jpn J Infect Dis; 2016 May; 69(3):221-3. PubMed ID: 26255735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel cell-based high throughput assay to determine neutralizing antibody titers against circulating strains of rubella virus.
    Kanbayashi D; Kurata T; Takahashi K; Kase T; Komano J
    J Virol Methods; 2018 Feb; 252():86-93. PubMed ID: 29191395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroepidemiology of rubella in northern Greece.
    Gioula G; Diza-Mataftsi E; Alexiou-Daniel S; Kyriazopoulou-Dalaina V
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):631-3. PubMed ID: 15243817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide rubella epidemic--Japan, 2013.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(23):457-62. PubMed ID: 23760185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rubella Seroprevalence among the General Population in Dongguan, China.
    Lin W; Wang D; Xiong Y; Tang H; Liao Z; Ni J
    Jpn J Infect Dis; 2015; 68(3):192-5. PubMed ID: 25672349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Herd immunity against rubella according to a survey of the population in Medellin, Colombia].
    Hincapié Palacio D; Ospina Giraldo J; Lenis Ballesteros V; Ospina Ospina MC; Arroyave Cadavid M; Hoyos Muñoz N; Almanza Payares R
    Rev Panam Salud Publica; 2012 Aug; 32(2):101-8. PubMed ID: 23099870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.